genocea-biosciences-cover-image

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases. Traditional discovery methods have proven unable to identify the targets of immune response. ATLAS, Genocea's proprietary technology platform, mimics the human immune system to identify the targets most likely to illicit an immune response. Genocea's pipeline of novel, clinical-stage, T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for pneumococcus, and earlier-stage programs in chlamydia, malaria and cancer immunotherapy.

Nulla adipisicing do ut aliquip elit tempor fugiat. Mollit est exercitation excepteur ea consequat ullamco Lorem ex id. Ipsum nostrud Lorem dolor nisi do est in ex amet eu nostrud. Amet commodo consectetur enim nostrud dolore sint excepteur irure aliqua consectetur. Veniam occaecat et enim eiusmod qui fugiat eiusmod eiusmod laborum exercitation veniam ipsum velit. Ut veniam cupidatat ea tempor ad ad exercitation amet qui. Esse commodo sint deserunt ut elit minim sint. Amet laborum ut adipisicing minim sunt cillum anim in est ipsum aliquip anim in tempor pariatur.

industries

Biology Biochemistry

Advancing Human Health

Milestones

Lux founded: 2006

IPO (NASDAQ: GNCA) 2014

Founders
Lux partners
No items found.

Genocea Biosciences

Andrew Wilson
Jasmine Rainey
Tracie Rotter
Stevie Lee
Steven Brody
Shaq Vayda
Shahin Farshchi, PhD
Segolene Scarborough
Sean Traynor
Scott Rubin
Saunaz Moradi
Samuel Arbesman, PhD
Samantha Cho
Peter Hébert
Lindsay Morris
Lan Jiang
Josh Wolfe
Grace Isford
Deena Shakir
Debbie Elsen
Danny Crichton
Dana Riley
Cristina Morris
Chris Gates
Bree Morgan
Brandon Reeves
Brad Gritsch
Bilal Zuberi
Bibi Masara
Alex Nguyen
Adam Kalish